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AbstrAct
Background. Camptothecin (CPT), an alkaloid isolated from the Chinese tree Camptotheca acuminata, 
exhibits very high anticancer activity. CPT is a fluorescent compound and this is a very useful property. 
Using methods of fluorescence spectroscopy, one can determine or predict the biophysical properties 
of this promising compound. The cellular target of CPT is topoisomerase I. CPT interacts only with those 
cells which are in the S-phase. CPT molecules bind to topoisomerase I – DNA complex and prevent the 
replication process. This means that CPT is toxic to those cells that are undergoing DNA synthesis. Can-
cerous cells are rapidly replicating and they spend more time in the S-phase in relation to healthy tissues, 
and therefore they are killed with much higher efficiency than the healthy host tissues. Such selectivity of 
cytotoxicity is a promising property of CPT. Due to the S-phase specificity of CPT, a continuous exposure 
to this drug must be maintained in order to achieve optimum therapeutic efficacy.
Materials and methods. We used fluorescence anisotropy measurements to determine the properties of 
binding to membranes and proteins of two anticancer agents: 7-tert-butyldimethylsilyl-camptothecin and 
7-tert-butyldimethylsilyl- 10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin. The samples of CPT, 
1Si-CPT and 2Si-CPT were obtained from the laboratory of biotechnology, College of Pharmacy, University 
of Kentucky, Lexington, USA. 2 mM stock solutions of CPT, 1Si-CPT and 2Si-CPT were prepared in DMSO. 
As model membranes, small unilamelar liposomes formed by DMPC and DMPG lipids were used.
Results. Fluorescence anisotropy measurements prove that this new camptothecin analogue exhibits 
desirable properties: high affinity of lactone form to membranes and low affinity of carboxylate form to 
HSA. Such properties should ensure high stability of this drug in physiological fluids, including blood. 
The second considered compound, 7-tert-butyldimethylsilyl- camptothecin, exhibits very high affinity of its 
lactone form to membranes, but its carboxylate form exhibits also high affinity to HSA. The latter property 
excludes this compound as a candidate to be a good anticancer drug.
Conclusions. Fluorescence anisotropy measurements show that the lactone forms of 1Si-CPT and 2Si-CPT 
exhibit a high affinity to membranes but only the carboxylate form of 2Si-CPT behaves in a desirable way in 
HSA solution i.e. it exhibits a low affinity to this protein. This means that 2Si-CPT could be an excellent candi-
date for further in vivo pharmacological studies, and most probably for clinical trials in cancer chemotherapy.
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Introduction
Camptothecin (CPT), an alkaloid isolated from the 
Chinese tree Camptotheca acuminata, exhibits very high 
anticancer activity [1]. CPT is a fluorescent compound 
and this is a very useful property. Using methods of 
fluorescence spectroscopy, one can determine or 
predict the biophysical properties of this promising 
compound. CPT can exist in two forms: lactone (stable 
at pH < 5.5) and carboxylate (stable at pH > 9). The 
chemical structures of both forms of camptothecins 
are presented in Figure 1 and Table 1. Only the lactone 
form is biologically active. The cellular target of CPT is 
topoisomerase I, a nuclear enzyme responsible for DNA 
replication. CPT interacts only with those cells which are 
in the S-phase. CPT molecules bind to topoisomerase 
I – DNA complex and prevent the replication process 
[2, 3]. This means that CPT is toxic to those cells that are 
undergoing DNA synthesis. Cancerous cells are rapidly 
replicating and they spend more time in the S-phase 
in relation to healthy tissues, and therefore they are 
killed with much higher efficiency than the healthy host 
tissues. Such selectivity of cytotoxicity is a promising 
property of CPT. Due to the S-phase specificity of CPT, 
a continuous exposure to this drug must be maintained 
in order to achieve optimum therapeutic efficacy. Unfor-
tunately, there is some difficulty in fulfilling this require-
ment. Under physiological conditions (pH = 7.4), CPT 
hydrolyses and converts to the ‘ring opened’ inactive 
carboxylate form [3]. After about two hours, equilibrium 
is achieved and both forms coexist. The concentration of 
the lactone form in equilibrium is much smaller than the 
carboxylate form, and depends on the environment in 
which the CPT is incubated. This is about 15%, 5% and 
0.2% for PBS (phosphate buffer saline), whole blood, 
and blood plasma, respectively [4]. The low concentra-
tion of the lactone form under physiological conditions 
seriously limits the possible application of CPT in cancer 
chemotherapy. The presence of human serum albumin 
(HSA) has a critical influence on the activity of camp-
tothecin. Two hours after introducing camptothecin to 
an HSA solution, it has totally lost its anticancer activity. 
Camptothecin carboxylate molecules bound to HSA do 
not convert into the lactone form. This leads to rapid 
decay of the active lactone form in blood [5]. However, 
a competing effect exists which improves the stability 
of camptothecin: CPT molecules bound to membranes 
do not hydrolyse [6]. 
Much effort has been undertaken in order to discover 
analogues of camptothecin which exhibit improved 
blood stability. Such new compounds should retain 
anticancer properties and exhibit high affinity of the 
lactone forms to membranes and low affinity of the 
carboxylate forms to HSA. Obtaining and studying 
camptothecin analogues has become a major chal-
lenge for many laboratories. Hundreds of analogues 
have been synthesised. Some selected camptothecin 
analogues are set out in Table 1 and Figure 1. Two of 
them, topotecan and irinotecan, have been approved 
by the FDA (US Food and Drug Administration) and are 
used in the chemotherapy of many tumours. These CPT 
analogues exhibit stability in blood that is higher than 
that of CPT. The equilibrium concentration of the active 
form in blood is equal to 12% for topotecan and 21% for 
irinotecan [7]. The increase in equilibrium concentration 
of these analogues is the result of weak binding of their 
carboxylate forms with HSA [7, 8]. Silatecans (chemical 
structures of some these agents are set out in Table 1) 
are a new class of promising camptothecin ana-
logues. Three silatecans: DB-67 (7-tert-butyldimethyl-
sil-10-hydroxy-camptothecin), DB-174 (7-trimethylsi-
lyl-ethyl-10-hydroxy-camptothecin), and 7-TMSiE-10-
A-CPT (7-trimethylsilyl-ethyl-10-amino-camptothecin) 
were the subjects of our previous studies [9–13]. Each 
of these three previously studied agents fulfills the crite-
rion of desirable CPT analogue. Carboxylate forms of the 
above silatecans exhibit weak affinity to HSA, and their 
lactone forms exhibit a very high affinity to membranes. 
Two other silatecans: 7-tert-butyldimethylsilyl-campto-
thecin and 7-tert-butyldimethylsilyl-10-[4-(1-piperidino)-
1-piperidino]-carbonyloxy- camptothecin, are the subject 
of this paper. We will call these CPT analogues ‘1Si-CPT’ 
and ‘2Si-CPT’, respectively. The chemical structures of 
these compounds are presented in Figure 2. The first of 
them (1Si-CPT), as can be seen in Table 1 and Figure 2, is 
obtained by substitution of hydrogen atom in position 7 of 
CPT molecule with the group  Si(CH3)2C(CH3)3. This is the 
same position 7 as in DB-67, widely studied in previous 
papers. Some selected results of preliminary studies of 
this compound have been presented [5, 14, 15]. 
The second compound (2Si-CPT) is obtained 
by substitution of hydrogen atoms in position 7 by 
 Si(CH3)2C(CH3)3 group (the same as in 1Si-CPT and DB-67) 
and in position 10 by  O2CNC5H4NC5H5. The latter is the 
same as 10 position group of irinotecan, the first CPT 
analogue approved by the FDA as an anticancer drug. 
The results of the studies of the behaviour of these 
two agents, 1Si-CPT and 2Si-CPT, in the presence of 
model membranes — liposomes and in HSA solutions 
are presented in the next parts of this paper.
Materials and methods 
Materials 
The samples of camptothecin (CPT), 7-tert-butyldi-
methylsilyl-camptothecin (1Si-CPT) and 7-tert-butyldi-
methylsilyl-10-[4-(1-piperidino)-1-piperidino]-carbony-
loxy-camptothecin (2Si-CPT) were obtained from the 
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laboratory of biotechnology, College of Pharmacy, 
University of Kentucky, Lexington, USA. 2 mM stock 
solutions of CPT, 1Si-CPT and 2Si-CPT were prepared 
in DMSO (dimethylsulfoxide, C2H6OS). Such stock 
solutions contain only a pure lactone form. 1 mM stock 
carboxylate solutions were obtained by diluting stock 
lactone solutions in phosphate buffered saline (PBS) at 
pH 12 in a volume ratio of 1:1. 
As model membranes, small unilamelar liposomes 
formed by DMPC (dimyristoyl- phosphatidylcholine) and 
DMPG (dimyristoyl phosphatidylglycerol) lipids were 
used. DMPC and DMPG were purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). The small unilamelar 
liposomes were prepared in the following way. Stock 
lipid suspensions in a phosphate buffered saline at 
pH of 7.4 and temperature of 37°C were prepared by 
Table 1. Structure of camptothecin and its analogues 
Compound R7 R9 R10
Camptothecin (CPT) H H H
Topotecan (TPT) H CH2N(CH3)2 OH
Irinotecan (CPT-11) C2H5 H O2CNC5H4NC5H5
DB-67 Si(CH3)2C(CH3)3 H OH
DB-174 (CH2)2Si(CH3)3 H OH
7-TMSiE-10-A-CPT (CH2)2Si(CH3)3 H NH2
1Si-CPT Si(CH3)2C(CH3)3 H H
2Si-CPT Si(CH3)2C(CH3)3 H O2CNC5H4NC5H5
Figure 1. Chemical structure of camptothecin and its analogues
Figure 2. Chemical structure of 1Si-CPT (7-tert-butyldimethylsilyl-camptothecin) and 2Si-CPT (7-tert-butyldimethylsilyl-
-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin)
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Vortex mixing for 5–10 minutes and then sonicated 
using a bath sonicator (Ultrasonic Cleaner SONIC-5, 
POLSONIC, Poland) for a few hours until optical clarity 
was obtained. The desired concentration of lipids was 
obtained by the addition of the stock lipid suspensions 
to PBS at pH 7.4.
Human serum albumin (95–97%) was purchased 
from Sigma-Aldrich (USA). The solutions of HSA were 
prepared in PBS. The pH of these solutions was kept 
at 7.4 and their temperature at 37°C. 
For fluorescence spectra recording and fluores-
cence anisotropy measurements, the concentrations 
of CPT, 1Si-CPT and 2Si-CPT in the final samples 
were equal to 2 μM. The desired concentrations were 
obtained by the addition of the stock solutions of camp-
tothecins under consideration to PBS at pH of 7.4 or to 
DMPC or DMPG liposomes suspensions at pH of 7.4, 
or to HSA solutions also at pH of 7.4. 
Method of anisotropy measurement
Fluorescence light of solution is always depolarised 
[16]. For characterisation of depolarisation degree of flu-
orescence light, the fluorescence anisotropy r, defined as  
               
r =
  IV – GIH
 IV + 2GIH
 
 
[16], is most often used. IV and IH are the fluorescence 
intensities of the vertically and horizontally polarised 
emission, when the sample is excited by vertically 
polarised light.
 
G =
  SV
 SH  
is the ratio of the sensitivities of the detection system 
for vertically and horizontally polarised light. On the 
basis of fluorescence anisotropy measurements in de-
pendence on concentration of lipids forming the model 
membranes, the association (binding) constants of 
drugs to membranes were determined. The association 
constant is determined by the formula: [17]
K = 
AB = 
FB
 AFL FFL 
,    (1)
where AF represents the concentration of free drug, 
AB is the concentration of drug bound to membranes, 
and L represents the total concentration of lipids form-
ing membranes. FF = AF/A is a fraction of free drug, 
FB = AB/A is the fraction of bound drug and A = AF + AB 
represents the total concentration of drug (the same 
for all samples).
The association constant K is a quantitative mea-
sure of affinity of drug to membranes. The procedure 
for determining the association constant on the basis 
of fluorescence anisotropy measurements has been 
described in detail in previous papers [10, 12]. 
Instrumentation
A PTI (Photon Technology International, Birming-
ham, NJ, USA) spectrofluorometer was used to record 
steady-state emission fluorescence spectra and to 
measure steady-state fluorescence anisotropy. To 
obtain the fluorescence spectra of CPT, 1Si-CPT and 
2Si-CPT, lights at 374, 377 and 376 nm respectively 
were used for excitation. Measurements of fluores-
cence anisotropy were performed with the instrument 
in the ‘L-format’ using excitation at 375 nm and 420 nm 
long-pass filters on the emission channel. Using a long 
pass filter on the emission channel ensures the separa-
tion of fluorescence from scattered light. The tempera-
ture of the samples was kept constant (37°C) using the 
ultrathermostat TW2.03 (ELMI).
results and discussion
Figure 3 presents the steady-state fluorescence 
spectra of lactone forms of 1Si-CPT, 2Si-CPT and com-
parable spectra of CPT. These compounds were diluted 
in PBS and in suspensions of liposome formed from 
DMPC and DMPG lipids. The concentration of DMPC 
lipids, as well as DMPG lipids used for the preparation of 
liposomes, was 1.5 mM. Spectra presented in Figure 3 
are pure fluorescence spectra – the contribution of 
scattered light was removed by subtracting the scat-
tering spectrum of PBS (or PBS and liposomes) from 
the recorded fluorescence spectrum of drug (1Si-CPT, 
2Si-CPT and CPT). Emission fluorescence spectra of 
1Si-CPT diluted in PBS, as shown in Figure 3A, exhib-
ited maximum at 450 nm, while for 1Si-CPT diluted in 
suspension of DMPC liposomes, as well as DMPG lipo-
somes, an increase in fluorescence intensity and a shift-
ing toward shorter wavelengths (maximum at 439 nm for 
DMPC and at 437 for DMPG) were observed. Figure 3B 
presents analogical spectra of lactone form of 2Si-CPT 
diluted in PBS and in 1.5 mM suspensions of DMPC 
as well as DMPG liposomes. 2Si-CPT diluted in PBS 
exhibits fluorescence with a maximum at 457 nm. After 
incubation of this compound in liposomes suspension, 
as with 1Si-CPT, an increase in fluorescence intensity 
and a shifting toward shorter wavelengths (maximum 
at 443 nm for both DMPC and DMPG liposomes) were 
observed. The change in fluorescence spectra of 1Si-CPT 
and 2Si-CPT, after their incubation in liposomes sus-
pensions, may prove strong binding of these agents 
to liposomes. It should be noted that, unlike 1Si-CPT 
and 2Si-CPT, the difference in fluorescence spectrum 
of the lactone form of CPT diluted in PBS and 1.5 mM 
DMPC liposomes suspension, as shown in Figure 3C, 
was not observed. 
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This proves that, unlike the two new camptothecin 
analogues considered here, CPT lactone exhibits poor 
binding to liposomes. Previous authors [17] have ob-
served a 16 nm shifting of fluorescence spectrum of 
CPT after incubation of it in liposomes suspension, but 
they used very high concentrated liposomes (290 mM). 
For quantitative determination of 1Si-CPT and 2Si-CPT 
binding to liposomes, the fluorescence anisotropy as 
a function of lipids concentration was measured. The 
results of such measurements are presented in Figure 4. 
The fast increase of anisotropy with increasing lipids 
concentration was observed for 1Si-CPT and 2Si-CPT. 
This means that these two compounds bind very easily 
to membranes. The changes in fluorescence anisot-
ropy of the parent drug CPT over lipid concentration 
are also for comparison depicted in Figure 4. The rate 
of fluorescence increase in this case is weak, which 
means that CPT binds poorly to DMPC and DMPG 
liposomes. However, the new CPT analogues under 
consideration here generally exhibit a high rate of an-
isotropy increase, although differences in behaviour 
of 1Si-CPT and 2Si-CPT in the presence of liposomes 
exist: (1) Anisotropy of free 1Si-CPT (in PBS) is smaller 
than anisotropy of free 2Si-CPT; observed differences in 
the value of anisotropies may be the result of differences 
in molecular weight of these two compounds (MW of 
1Si-CPT = 472, while MW of 2Si-CPT = 673), and/or 
may be the result of a difference in fluorescence life time 
Figure 3. Steady-state fluorescence spectra of: (A) lactone form of 1Si-CPT diluted in PBS and in suspensions of DMPC 
and DMPG liposomes; (B) lactone form of 2Si-CPT diluted in PBS and in suspensions of DMPC and DMPG liposomes 
and; (C) lactone form of CPT diluted in PBS and in suspensions of DMPC liposomes. The concentration of liposomes was 
the same in each case (1.5 mM DMPC lipids and 1.5 mM DMPG lipids were used to prepare liposomes suspensions).
Figure 4. Steady-state fluorescence anisotropy of 1Si-CPT, 2Si-CPT and CPT depending on DMPC (A) and DMPG (B) 
liposomes concentration.
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of these two compounds [16]; (2) The rate of anisot-
ropy rise of 1Si-CPT in DMPC liposomes suspension 
is higher than the rate of anisotropy rise of 2Si-CPT; 
this indicates that 1Si-CPT exhibits a higher affinity to 
DMPC liposomes than 2Si-CPT does; (3) The rates 
of anisotropy rise of 1Si-CPT and 2Si-CPT in DMPG 
liposomes suspension are comparable; we may then 
suppose that the affinities of 1Si-CPT and 2Si-CPT to 
DMPG are comparable; (4) Saturation fluorescence 
anisotropy value in both DMPC and DMPG liposomes 
is smaller for 1Si-CPT (~ 0.20) than for 2Si-CPT 
(~ 0.30); this could be explained as a result of differ-
ences in the sizes of the complexes liposome – bound 
drug (complexes ‘liposome - bound 1Si-CPT’ most 
probably are smaller than complexes ‘liposome 
— bound 2Si-CPT’) and/or a difference in fluorescence 
life time of these two compounds [16]. 
On the basis of experimentally determined anisotro-
py using previously described methods, the concentra-
tions of free and bound drugs in liposomes suspension 
were calculated and then the double reciprocal plots 
were drawn. They are shown in Figure 5. The slope 
of lines fitted to experimental values determined the 
inverse of association constants (1/K). The obtained 
parameters are summarized in Table 2. The value of 
association constants of CPT and previously studied 
silatecans are also set out in Table 2.
The results set out in Table 2 show that 1Si-CPT ex-
hibits the highest affinity to liposomes, and values of this 
affinity (association constants) are almost the same for 
DMPC and DMPG liposomes. They are at least 150-fold 
higher than the association constants of camptothecin. 
2Si-CPT exhibits also a high affinity to liposomes, but not 
as high as 1Si-CPT. Additionally, in the case of 2Si-CPT, 
a difference in affinity to DMPC and DMPG exists. The 
DMPC molecule is electrically neutral, while DMPG is 
negatively charged. Molecules of lactone forms of CPT, 
1Si-CPT, DB-67, DB-174, and 7-TMSiE-10-A-CPT are 
electrically neutral, and therefore for each of these drugs 
affinity to DMPC liposomes is comparable with affinity 
to DMPG liposomes. Substituent group at position 10 in 
2Si-CPT is positively charged and therefore this drug 
Figure 5. Double-reciprocal plots for the binding of lactone forms of 1Si-CPT, 2Si-CPT and CPT to the DMPC (A) and 
DMPG (B) liposomes
Table 2. Association constants of lactone forms of camptothecin, previously studied silatecans (DB-67, DB-174, 
7-TMSiE-10-A-CPT) and new camptothecin analogues — silatecans 1Si-CPT and 2Si-CPT to DMPC and DMPG 
liposomes determined by fluorescence anisotropy method
Compound KDMPC (M
-1) KDMPG (M
-1) References
CPT 70 ± 15
100 ± 15
–
100 ± 15
[10]
[5, 12]
DB-67 4,500 ± 900
6,600 ± 1,000 
3,000± 600
–
[5, 12]
[10]
DB-174 9,000 ± 1,000 6,600 ± 800 [12]
7-TMSiE-10-A-CPT 5,700 ± 800 – [13]
1Si-CPT 15,500 ± 800
15,000 ± 1,000
16,000 ± 800 
16,000±1,000
[5, 14, 15]
–
2Si-CPT 2,500 ± 500 12,000 ± 1,000 –
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exhibits a higher affinity to negatively charged DMPG 
liposomes than to neutral DMPC liposomes. 
The results of measurements of affinity of 1Si-CPT 
and 2Si-CPT to liposomes show that the two campto-
thecin analogues under consideration have promising 
properties. High lipophilicity of lactone forms of camp-
tothecin analogues however, is not sufficient to assure 
high stability in blood and physiological fluids. The 
second desired property of camptothecin analogues 
is low affinity of their carboxylate forms to HSA. The 
results of studies by steady-state fluorescence anisot-
ropy measurements of the behaviour of carboxylate 
and lactone forms of CPT, 1Si-CPT and 2Si-CPT in HSA 
solution, are presented in Figure 6. Figure 5A shows the 
steady-state fluorescence anisotropy of the carboxy-
late form of CPT in HSA solution is large and does not 
change over time, which proves that the molecules of 
CPT carboxylate are bound to big HSA molecules. CPT 
lactone just after incubation in HSA solution exhibits low 
steady-state anisotropy, which means that CPT lactone 
does not bind, or binds poorly, to HSA. However, the 
anisotropy rises over time. This increase is caused by 
the hydrolysis process. The free CPT lactone molecules 
convert into carboxylate, which immediately binds to 
HSA. After about two hours, as shown in Figure 6A, 
the anisotropy approaches that obtained for the pure 
carboxylate form. This means that after such time, the 
lactone form is converted almost totally to inactive car-
boxylate. Figure 6B shows that 1Si-CPT behaves in an 
HSA solution similar to CPT. Fluorescence anisotropy of 
the carboxylate form of 1Si-CPT is high, which means 
that this compound exhibits a high affinity to HSA. On 
the other hand, anisotropy of the lactone form is small, 
but it converts into carboxylate, which immediately binds 
to HSA, which results, as shown in Figure 6B, in an in-
crease in fluorescence anisotropy. Figure 6C shows that 
2Si-CPT, compared to CPT and 1Si-CPT, behaves totally 
differently in an HSA solution. Fluorescence anisotropy of 
both forms of this analogue is rather small, which means 
that both forms of this agent exhibit a low affinity to HSA. 
This is a desired property. Low affinity of the carboxylate 
form of 2Si-CPT to HSA, together with high affinity of its 
lactone form to membranes, ensures a sufficiently high 
stability of its lactone form in blood and in physiological 
fluids. Unlike 2Si-CPT, 1Si-CPT, despite its very high 
affinity to membranes, behaves undesirably in HSA solu-
tions, and it may be supposed that this compound will 
behave badly in blood and in physiological fluids i.e. its 
lactone form will be transformed to inactive carboxylate 
form and this will be an irreversible transformation. It 
can therefore be supposed that after about 2–3 hours, 
the concentration in blood of the active lactone form of 
1Si-CPT drops to zero. Because of such undesirable 
properties, 1Si-CPT will probably be excluded from fur-
ther studies. The second silatecan studied here, 2Si-CPT, 
because of its desirable properties will be attached to 
a group of promising anticancer drugs such as DB-67, 
DB-174, and 7-TMSiE-10-A-CPT as a good candidate for 
further studies, including studies on animals. 
conclusion
Fluorescence anisotropy measurements show that 
the lactone forms of 1Si-CPT and 2Si-CPT exhibit a high 
affinity to membranes (a desirable property of camp-
tothecin analogues), but only the carboxylate form of 
2Si-CPT behaves in a desirable way in HSA solution i.e. 
it exhibits a low affinity to this protein. This means that 
2Si-CPT could be an excellent candidate for further in vivo 
pharmacological studies, and most probably for clinical 
trials in cancer chemotherapy. Despite the very high 
Figure 6. Time evolution of steady-state fluorescence anisotropy of lactone and carboxylate forms of CPT (A), 1Si-CPT (B) 
and 2Si-CPT (C) in 10 mM HSA solutions.
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affinity of the lactone form of 1Si-CPT to membranes, the 
carboxylate form of this CPT analogue exhibits a high 
affinity to HSA, and therefore this compound will most 
probably be excluded from further studies. The high 
affinity of carboxylate form of 1Si-CPT to HSA proves 
that its stability in blood will be low.
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